Opthea H2 2025 Earnings Report

Opthea EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.05
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Opthea Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.07 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Opthea Announcement Details

• Quarter: H2 2025
• Date: 9/5/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, September 11, 2025
• Conference Call Time: 8:00PM ET

Opthea (NASDAQ:OPT) Limited (NASDAQ:OPT) is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal vascular diseases. The company’s lead product candidate, OPT-302, is designed to inhibit vascular endothelial growth factors C and D (VEGF-C/D) and is being evaluated as a potential treatment for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s research strategy aims to complement existing anti-VEGF-A therapies by providing a broader blockade of the VEGF family to address residual vision loss in patients receiving standard care.

OPT-302 has advanced through multiple clinical trials, including a Phase 2b study in wet AMD patients and a Phase 1/2 trial in DME patients. Data from these trials have demonstrated promising safety and efficacy signals, including improvements in visual acuity and reductions in retinal fluid. Opthea collaborates with global contract research organizations and ophthalmology centers to support its clinical development program, with ongoing studies designed to establish optimal dosing regimens and confirm long-term benefits.

Founded in 2009 based on research conducted at the Walter and Eliza Hall Institute in Melbourne, Opthea is headquartered in Melbourne, Australia, with strategic operations in North America. The company’s management team combines expertise in ophthalmology, clinical development, regulatory affairs and commercialization to advance its pipeline toward potential regulatory approvals. Opthea is committed to addressing unmet medical needs in retinal diseases and to creating value for patients, healthcare providers and investors through its innovative therapeutic approach.